Recce Pharmaceuticals Wins $2M Defense Grant For Revolutionary Burn Treatment

Recce Pharmaceuticals Ltd has been awarded a $2 million grant by the U.S. Department of Defense to accelerate the development of its RECCE 327 Gel, aimed at treating burn wound infections and preventing sepsis in military environments. This grant will facilitate the assessment of RECCE 327 Gel as a viable alternative to conventional antimicrobial dressings. Coupled with a successful A$8 million institutional placement and an open share purchase plan, this funding underscores Recce’s expanding impact in the medical sector and its dedication to enhancing health outcomes.